Enhance Your Immuno-oncology Research with Knock-Out Cell Lines

Discover the power of using knock-out cell lines combined with high-throughput assays to gain a deep understanding of immuno-oncology pathways and identify novel pharmaceutical targets

The interaction of programmed death-ligand 1 (PD-L1) with the receptor PD-1 inhibits T cell activity and proliferation, facilitating immune evasion by cancer cells.

Identifying inhibitory signals, such as PD-L1, on the surface of cancer cells has triggered the development of a new class of cancer immunotherapy that interferes explicitly with immune silencing.

Learn how disrupting genes within immuno-oncology pathways, such as the PD-L1 pathway, using CRISPR gene-editing can help elucidate the contribution of individual genes, enabling the identification of disease mechanisms and therapeutic targets.

This application note uses the PD-L1 pathway as an example to demonstrate the utility of a highly validated knock-out cell line and the complementary power of co-culture and high-throughput multiplex assays for investigating key pathways involved in immune evasion.

All emails contain an unsubscribe link. You can review our privacy policy, cookie policy and terms and conditions online.